Welcome to our dedicated page for Longboard Pharmaceuticals news (Ticker: $LBPH), a resource for investors and traders seeking the latest updates and insights on Longboard Pharmaceuticals stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Longboard Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Longboard Pharmaceuticals's position in the market.
Longboard Pharmaceuticals, Inc. announced the grant of inducement awards to seven new employees, including options to purchase 178,000 shares of Common Stock. The options were granted to attract new talent and retain employees, with a vesting schedule over time.
Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH) reported positive topline data for Bexicaserin in Q1 2024, with plans for a global Phase 3 program by YE 2024. The company also announced $321.0 million in cash reserves, supporting operations into 2027. Longboard's President and CEO, Kevin R. Lind, expressed optimism for the future and shared upcoming milestones, including Phase 1 SAD data for LP659 in Q2 2024.